- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | MapLight Therapeutics to join Russell 3000, Russell 2000 and Russell Microcap indexes | 1 | Seeking Alpha | ||
| 04.12. | MapLight Therapeutics, Inc.: MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress | 91 | GlobeNewswire (Europe) | Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026Topline results from Phase 2 VISTA trial of ML-007C-MA for Alzheimer's disease psychosis... ► Artikel lesen | |
| 04.12. | MapLight Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| MAPLIGHT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 04.12. | MapLight Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.12. | MapLight stock rises as Jefferies reiterates Buy rating on schizophrenia drug | 1 | Investing.com | ||
| 03.12. | Jefferies bekräftigt "Buy"-Rating: MapLight-Aktie legt dank Schizophrenie-Wirkstoff zu | 1 | Investing.com Deutsch | ||
| 21.11. | Leerink Partners startet Coverage für MapLight Therapeutics mit "Outperform" | 3 | Investing.com Deutsch | ||
| 21.11. | MapLight Therapeutics stock initiated with Outperform rating by Leerink Partners | 1 | Investing.com | ||
| 21.11. | Jefferies startet Coverage für MapLight Therapeutics mit Kaufempfehlung und hohem Kurspotenzial | 2 | Investing.com Deutsch | ||
| 21.11. | MapLight Therapeutics stock initiated with Buy rating at Jefferies | 1 | Investing.com | ||
| 21.11. | Morgan Stanley initiates MapLight Therapeutics stock with Overweight rating | 1 | Investing.com | ||
| 21.11. | MapLight Therapeutics stock initiated with Buy rating by Stifel | 1 | Investing.com | ||
| 21.11. | Morgan Stanley startet Coverage für MapLight Therapeutics mit "Overweight" und sieht 156 % Kurspotenzial | - | Investing.com Deutsch | ||
| 30.10. | Inflammation biotech Evommune prices IPO after MapLight's $250M debut | 1 | FierceBiotech | ||
| 29.10. | MapLight Therapeutics completes $296 million IPO on nasdaq | 6 | Investing.com | ||
| 29.10. | MapLight Therapeutics, Inc.: MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | 337 | GlobeNewswire (Europe) | SAN FRANCISCO and BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating... ► Artikel lesen | |
| 29.10. | MapLight Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 28.10. | MapLight shares track up after $251m IPO | 2 | pharmaphorum | ||
| 27.10. | MapLight Therapeutics debuts on Nasdaq at $19, above $17 IPO price | 2 | Investing.com | ||
| 27.10. | CNS disorder biotech MapLight Therapeutics prices IPO at $17, as expected | 1 | Renaissance Capital |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STRUCTURE THERAPEUTICS | 67,44 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs | SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| ARCELLX | 72,69 | 0,00 % | Stifel upgrades Arcellx stock, cites buying opportunity after share weakness | ||
| AVIDITY BIOSCIENCES | 71,60 | +0,35 % | Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity | ||
| PRAXIS PRECISION MEDICINES | 267,28 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 | BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| IMMUNOVANT | 24,810 | 0,00 % | Immunovant: 550-Millionen-Dollar-Kapitalerhöhung und neue Studiendetails | ||
| COGENT BIOSCIENCES | 40,040 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 81,70 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 14,070 | 0,00 % | Hagens Berman Sobol Shapiro LLP: MoonLake Immunotherapeutics' (MLTX) Stock Crashes 90%, Triggers Lawsuit After Reported Phase 3 Trial Data for Sole Drug Candidate -- Hagens Berman | SAN FRANCISCO, Nov. 28, 2025 /PRNewswire/ -- MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company, has been hit with a securities... ► Artikel lesen | |
| DYNE THERAPEUTICS | 19,420 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven... ► Artikel lesen | |
| VERA THERAPEUTICS | 46,020 | 0,00 % | Vera Therapeutics, Inc. - 8-K, Current Report | ||
| MINERALYS THERAPEUTICS | 36,050 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 - - Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 - - Conference call... ► Artikel lesen | |
| FULCRUM THERAPEUTICS | 12,800 | 0,00 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting | ? Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12): mean absolute HbF in the 20 mg cohort increased by 9.9% at... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 87,81 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 31,550 | 0,00 % | Olema Pharmaceuticals stock price target raised to $45 at H.C. Wainwright | ||
| RECURSION PHARMACEUTICALS | 4,580 | 0,00 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen |
Das Unternehmen MAPLIGHT THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 20,095 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAPLIGHT THERAPEUTICS INC finden Sie auf Wallstreet Online.